Investor Relations Contact:Barbara RyanEmail: firstname.lastname@example.orgPhone: 203-274-2825Media Contact:Lori GorskiEmail: email@example.comPhone: 617-551-4096
WALTHAM, Mass., April 21, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Deutsche Bank 41st Annual Health Care Conference on May 4, 2016 at 9:20 a.m. ET at the InterContinental Hotel, Boston, Mass. A live webcast of the presentation and presentation materials will be available on the Investors section of the Radius website at www.radiuspharm.com. An archived replay will be available for approximately 30 days following the presentation. About RadiusRadius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) was submitted in the U.S. at the end of the first quarter of 2016. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in multiple applications including cancer.